In a research note published yesterday, Roth Capital analyst Chris Lewis maintained a Buy rating on Nanosphere (NSPH) and cut his price target …
In a research note released yesterday, Roth Capital analyst Chris Lewis reaffirmed a Buy rating on Nanosphere (NSPH) with a $3 price target …
In a research report released today, Canaccord analyst Mark Massaro reiterated coverage with a “Buy” rating on Nanosphere, Inc. (NSPH) and a price target of $5.
Nanosphere, Inc. (NSPH) announced this morning that it received FDA clearance for the bacterial portion of its enteric pathogen (EP) test.
Roth Capital analyst Chris Lewis today maintained a Buy rating on Nanosphere, Inc. (NSPH), with a price target of $3.
